Status: Active
Supira Medical
- Status Current
- Sector Heart Failure
- Year Invested 2020
- HQ Campbell, CA, United States
- Clinical Activities Brazil, Paraguay
- Lead Partners Frederik Groenewegen
- David Thompson
Website supiramedical.com/
Related News
- Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States
- Supira Medical Initiates U.S. Early Feasibility Study (EFS) for High-Risk PCI
- Supira Medical Receives FDA Breakthrough Device Designation as the Company Closed $40M in Series D Financing
- Supira Medical Closes $30M in an Oversubscribed Series C Financing
- Supira Medical Closes $35M in Series B Financing
Percutaneous heart pump for high risk PCI and cardiogenic shock patients
Percutaneous ventricular assist devices are used during stent placement or angioplasty to provide mechanical support for high-risk patients with severe coronary artery disease or comorbidities. Additionally, pVADs are used to treat patients suffering from cardiogenic shock (CS), a condition that can occur following a severe heart attack and is associated with a high rate of morbidity as a patient's heart is suddenly too weak to adequately pump blood to vital organs.